Marinella Roberti

Prof. Marinella Roberti

Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JJJakub Jeřábek
Jakub Jeřábek
EUElisa Uliassi
Elisa Uliassi
LGLaura Guidotti
Laura Guidotti
Jan KorabecnyJan Korabecny
Jan Korabecny
OSOndřej Soukup
Ondřej Soukup
MBMaria Laura Bolognesi
Maria Laura Bolognesi

2 July 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
VPViola Previtali
Viola Previtali
GBGreta Bagnolini
Greta Bagnolini
ACAndrea Ciamarone
Andrea Ciamarone
GFGiovanni Ferrandi
Giovanni Ferrandi
FRFrancesco Rinaldi
Francesco Rinaldi
ACAndrea Cavalli
Andrea Cavalli
In recent years, synthetic lethality has been recognized as a solid paradigm for anticancer therapies. The discovery of a growing number of synthetic lethal targets has led to a significant expansion in the use of synthetic lethality, far beyond poly(ADP-ribose) polymerase inhibitors used to treat BRCA1/2-defective tumors. In particular, molecular targets within DNA damage response have provided a source of inhibitors that have rapidly reached clinical trials. This Perspective focuses on the most recent progress in synthetic lethal targets and their inhibitors, within and beyond the DNA damage response, describing their design and associated therapeutic strategies. We will conclude by discussing the current challenges and new opportunities for this promising field of research, to stimulate discussion in the medicinal chemistry community, allowing the investigation of synthetic lethality to reach its full potential.

18 April 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Marinella RobertiMarinella Roberti
Marinella Roberti
DPDaniela Pizzirani
Daniela Pizzirani
MRMaurizio Recanatini
Maurizio Recanatini
DSDaniele Simoni
Daniele Simoni
Stefania GrimaudoStefania Grimaudo
Stefania Grimaudo
Manlio TolomeoManlio Tolomeo
Manlio Tolomeo

1 March 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Marinella RobertiMarinella Roberti
Marinella Roberti
FSFabrizio Schipani
Fabrizio Schipani
GBGreta Bagnolini
Greta Bagnolini
DMDomenico Milano
Domenico Milano
EGElisa Giacomini
Elisa Giacomini
ACAndrea Cavalli
Andrea Cavalli

11 July 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ASAlessandra Salerno
Alessandra Salerno
FSFrancesca Seghetti
Francesca Seghetti
JCJessica Caciolla
Jessica Caciolla
EUElisa Uliassi
Elisa Uliassi
ETEleonora Testi
Eleonora Testi
MBMaria Laura Bolognesi
Maria Laura Bolognesi
Proteolysis targeting chimera (PROTAC)-mediated protein degradation has prompted a radical rethink and is at a crucial stage in driving a drug discovery transition. To fully harness the potential of this technology, a growing paradigm toward enriching PROTACs with other therapeutic modalities has been proposed. Could researchers successfully combine two modalities to yield multifunctional PROTACs with an expanded profile? In this Perspective, we try to answer this question. We discuss how this possibility encompasses different approaches, leading to multitarget PROTACs, light-controllable PROTACs, PROTAC conjugates, and macrocycle- and oligonucleotide-based PROTACs. This possibility promises to further enhance PROTAC efficacy and selectivity, minimize side effects, and hit undruggable targets. While PROTACs have reached the clinical investigation stage, additional steps must be taken toward the translational development of multifunctional PROTACs. A deeper and detailed understanding of the most critical challenges is required to fully exploit these opportunities and decisively enrich the PROTAC toolbox.

10 February 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
GBGreta Bagnolini
Greta Bagnolini
DMDomenico Milano
Domenico Milano
MMMarcella Manerba
Marcella Manerba
FSFabrizio Schipani
Fabrizio Schipani
JOJose Antonio Ortega
Jose Antonio Ortega
ACAndrea Cavalli
Andrea Cavalli
Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with BRCA mutations. Here, we exploit a new paradigm based on the possibility to triggers synthetic lethality using only small organic molecules (dubbed “fully small-molecule-induced synthetic lethality”). We exploited this paradigm to target pancreatic cancer, one of the major unmet needs in oncology. We discovered a dihydroquinolone pyrazoline-based molecule (35d), which disrupts the RAD51-BRCA2 protein-protein interaction, thus mimicking the effect of BRCA2 mutation. 35d inhibits the homologous recombination in a human pancreatic adenocarcinoma cell line. In addition, it synergizes with olaparib (a PARPi) to trigger synthetic lethality. This strategy aims to widen the use of PARPi in BRCA-competent and olaparib-resistant cancers, making fully small-molecule-induced synthetic lethality an innovative approach towards unmet oncological needs.